What D3 Bio does

D3 Bio is a clinical-stage biotechnology company founded in November 2020 and headquartered in Shanghai with R&D operations in Wuxi, China. The company develops precision oncology therapeutics, with its lead asset elisrasib (D3S-001) being a next-generation GDP-bound KRAS G12C inhibitor that covalently binds the OFF form of KRAS G12C to abolish nucleotide cycling between RAS Off and RAS On states, demonstrating rapid and complete target engagement, CNS penetration, and a favorable safety profile. The company is advancing elisrasib into global Phase III pivotal trials as monotherapy and in combination with pembrolizumab and an internal ERK1/2 inhibitor (D3S-002) for KRAS G12C-mutant non-small cell lung cancer, colorectal cancer, and pancreatic cancer across the United States, China, and the European Union.

The pipeline extends beyond elisrasib to include D3S-002, an ERK1/2 kinase inhibitor for vertical MAPK-pathway inhibition; D3S-003, a KRAS G12D inhibitor targeting the broader KRAS-mutant population; and D3L-001, a HER2×CD47 bispecific antibody for HER2-positive solid tumors. The company has secured FDA Fast Track Designation (2022), Orphan Drug Designations for pancreatic and colorectal cancers, and Breakthrough Therapy Designation for NSCLC (2025). Phase 2 first-line NSCLC data presented at ASCO 2026 reported 78.0% objective response rate for elisrasib monotherapy and 81.3% ORR for elisrasib plus pembrolizumab. D3 Bio owns global rights to all programs.

The business model is a traditional clinical-stage biotech commercialization pathway: develop innovative oncology therapeutics through clinical trials to regulatory approval, then commercialize globally via standard pharmaceutical distribution. The company is currently pre-revenue, funded by venture capital rather than product sales. Since launch D3 Bio has raised $370 million across a Series A ($200M, November 2020), a Series A+ led by Medicxi (April 2024), and a Series B ($108M, December 2025) with a syndicate including Temasek, WuXi AppTec, Boyu Capital, Matrix Partners China, Sequoia Capital China/HongShan, Medicxi, IDG Capital, HSG, MPCi, and SongQing Capital. Leadership is anchored by founder/CEO George Chen, MD (ex-AstraZeneca, 70+ INDs and 30+ NDAs directed) and co-founder/CFO/CBO John Jin, PhD (ex-BeiGene), with Antoine Yver, MD (former Daiichi Sankyo EVP) on the board.

Name

D3 Bio

Legal name

D3 Bio, Inc.

Website

https://d3bio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

D3 Bio is a clinical-stage biotechnology company developing next-generation KRAS inhibitors and targeted oncology therapeutics. Headquartered in Shanghai with R&D in Wuxi, China, it is advancing its lead asset elisrasib into global Phase III trials for KRAS G12C-mutant lung, colorectal, and pancreatic cancers.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

akta.pro secondary industries

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Oncology drug development
• KRAS inhibitor therapy
• Targeted cancer therapeutics
• Clinical-stage biotechnology
• Precision oncology medicines

Headquarters

HQ city

Wuxi Shi

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Drug Development and Commercialization: As a clinical-stage biotechnology company, D3 Bio's revenue model is based on developing and commercializing innovative oncology therapeutics. The company is advancing its pipeline through clinical trials toward regulatory approvals for global commercialization. The company owns global rights to all programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

D3 Bio is a clinical-stage biotechnology company developing precision oncology therapeutics, with lead asset elisrasib (D3S-001), a next-generation GDP-bound KRAS G12C inhibitor in global Phase III trials. The pipeline also includes D3S-002 (ERK1/2 inhibitor), D3S-003 (KRAS G12D inhibitor), and D3L-001 (HER2×CD47 bispecific antibody), each targeting tumor-driving mutations or immune pathways.

Product overview

D3 Bio is a clinical-stage biotechnology company developing a pipeline of oncology therapeutics targeting KRAS mutations and immune pathways. The core product is Elisrasib (D3S-001), a next-generation KRAS G12C inhibitor. The pipeline includes D3S-002 (ERK1/2 inhibitor), D3S-003 (KRAS G12D inhibitor), and D3L-001 (HER2×CD47 bispecific antibody). All programs target driver mutations or critical immune pathways with first-in-class or best-in-class potential, and D3 Bio owns global rights to all programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Elisrasib (D3S-001) Next-generation GDP-bound KRAS G12C inhibitor designed for rapid, complete, and selective target engagement. Covalently binds the GDP-bound (OFF) form of KRAS G12C, blocking nucleotide cycling and suppressing oncogenic signaling. Being evaluated in global Phase II/III clinical trials for NSCLC, CRC, and pancreatic cancer.
• D3S-002 ERK1/2 inhibitor for vertical inhibition of the MAPK pathway to improve anti-tumor activity and overcome resistance to KRAS G12C inhibitors. IND cleared by FDA.
• D3S-003 KRAS G12D inhibitor for KRAS-driven cancers. FDA IND cleared for Phase 1 trial.
• D3L-001 HER2×CD47 bispecific antibody that enhances phagocytosis and eradication of HER2-positive solid tumors via HER2 guided CD47 co-blocking. IND cleared by FDA for Phase 1 trial.

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Mirati Therapeutics (acquired by Bristol Myers Squibb): Developed Krazati (adagrasib), a KRAS G12C inhibitor that received accelerated FDA approval in December 2022 for NSCLC and is in development for CRC and other KRAS G12C-mutated tumors. Mirati is the most direct mechanistic competitor to elisrasib in the same target and indication space.
• Revolution Medicines: Clinical-stage oncology biotech developing RAS(ON) inhibitors including RMC-6236 (pan-RAS) and RMC-6291 (KRAS G12C(ON)), which target the active GTP-bound state of RAS. Its next-generation mechanism could leapfrog elisrasib's GDP-bound approach.
• Erasca: Clinical-stage precision oncology company developing therapies targeting the RAS/MAPK pathway, including ERK inhibitors and KRAS-targeting agents. Erasca's pipeline focus on the same signaling pathway makes it a direct mechanistic peer to D3 Bio's MAPK cascade strategy.

Broad incumbents

• Amgen: Developed Lumakras (sotorasib), the first FDA-approved KRAS G12C inhibitor (May 2021), with established commercial infrastructure in oncology. As the incumbent in KRAS G12C, Amgen represents the primary benchmark for elisrasib's clinical and commercial performance.
• AstraZeneca: Global pharmaceutical company with major oncology franchise and established KRAS programs (including Datroway and earlier-stage assets). D3 Bio's leadership including George Chen and Antoine Yver previously held senior oncology roles at AstraZeneca, providing direct relevance to its development approach.

Emerging players

• BridgeBio Pharma: Through its oncology subsidiary has pipeline programs targeting KRAS and the MAPK pathway. BridgeBio's clinical-stage KRAS efforts overlap with D3 Bio's vertical MAPK inhibition strategy.

Regional players

• BeiGene: Chinese-founded global oncology biotech with deep China-US clinical development capabilities, including Brukinsa (zanubrutinib). BeiGene shares the same founder/leadership DNA (George Chen and John Jin previously held senior roles at BeiGene) and similar global ambitions from a Chinese base.
• Innovent Biologics: Chinese clinical-stage biotech developing oncology therapeutics including PD-1 and KRAS-targeted therapies, with global development ambitions. Comparable as a China-anchored oncology biotech pursuing US/EU regulatory pathways.
• Junshi Biosciences: Chinese clinical-stage biotech with oncology pipeline including the PD-1 toripalimab and KRAS-targeting programs. Comparable as a Chinese biotech pursuing global oncology development and US regulatory approvals.
• Zai Lab: China-US biotech developing and commercializing innovative oncology therapeutics globally, including licensed and proprietary assets. Comparable business model as a Chinese-anchored oncology company pursuing US/China dual development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/d3bio

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about D3 Bio